학술논문

Application of a genetic signature of late GU toxicity in SCIMITAR, a Post-op SBRT trial
Document Type
article
Source
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Oncology and Carcinogenesis
Clinical Research
Genetics
Urologic Diseases
Cancer
Clinical Trials and Supportive Activities
Prostate Cancer
Radiation Oncology
6.5 Radiotherapy and other non-invasive therapies
SBRT
Genito-urinary toxicity
Germline biomarkers
PROSTOX
Oncology and carcinogenesis
Language
Abstract
Predictors of genitourinary toxicity after post-prostatectomy radiotherapy remain elusive. A previously defined germline DNA signature (PROSTOX) has shown predictive ability for late grade ≥ 2 GU toxicity after intact prostate stereotactic body radiotherapy. We explore whether PROSTOX would predict toxicity among patients receiving post-prostatectomy SBRT on a phase II clinical trial.